# Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck

> **NCT07682675** · PHASE2 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 51 (estimated)

## Conditions studied

- Adenoid Cystic Carcinoma of the Salivary Gland
- Recurrence
- Metastatic Disease

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07682675
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-04
- **Final completion:** 2032-04
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682675, "Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07682675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*